Auhtors: Sissung TM, Schmidt KT, Figg WD
DOI:https://doi.org/10.1016/S1470-2045(19)30003-8
Abstract
Insulin is responsible for cellular glucose uptake and mitogenic signalling cascades in cancer cells,1 and can promote cell proliferation, survival, invasiveness, angiogenesis, immunomodulation, and chemoresistance.1–3 Why, then, would some medical practitioners claim that the use of insulin and glucose can improve the outcomes of patients with cancer and facilitate cancer therapy de-escalation?4,5
